Frontlight ResearchEarly access
Not yet taking people in SwedenPhase 2
Comparing two abdominal chemotherapy treatments for bowel cancer spread to the abdominal lining
Tests two repeated abdominal chemotherapy treatments in adults with bowel cancer spread to the abdomen.
Key facts
- Who runs it
- Uppsala University Hospital
- Where
- Gothenburg, Malmo, Solna, and Uppsala, SwedenSee the 4 sites
- Trial code
- Registry title
- COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 60 people, planned
- Started
- 1 Aug 2026
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 15 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to under 80 with colorectal cancer that has spread to the lining of the abdomen (peritoneum) and cannot be treated with upfront surgery. It compares two repeat chemotherapy regimens given into the abdomen.
- Age
- 18 years or older and under 80 years
- Sex
- All sexes can join.
- Disease stage
- Colorectal cancer more than 10 cm (3.9 in) from the anal verge, with peritoneal metastases seen on CT scan, with or without the primary tumour. CT-PCI above 10, or below 10 if conversion therapy is needed before surgery. Considered a candidate for CRS/HIPEC surgery if the tumour responds well.
- Earlier treatment
- No previous treatment for the peritoneal metastases.
- Biomarker or test result
- Both RAS-mutated and RAS wild-type cancers can join. Deficient mismatch repair cancers cannot join.
Main reasons for not taking part
- Deficient mismatch repair cancer
- Previous CRS or HIPEC, or other large open abdominal surgery that caused adhesions
- Pregnant or breastfeeding
- Active infection needing antibiotics, active hepatitis B or C, or known HIV
- Lower or intermediate rectal cancer, or a need for radiation before surgery
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Provision of written informed consent prior to any study specific procedures. • ECOG Performance Status Score 0,1 or 2 alternatively Karnofsky 60-100 • Adequate kidney, liver, bone marrow function according to laboratory tests • For females of childbearing potential, a negative pregnancy test must be documented. • ≥ 18 years old and <80 years old • Colorectal cancer (>10cm from anal verge) with CT assessable synchronous or metachronous peritoneal metastases +/- primary tumor • CT-PCI > 10 (which translates often to surgical PCI >15) as judged at the HIPEC multidisciplinary board meeting but considered candidate for CRS/HIPEC in the case of significant tumor response. • CT-PCI < 10 allowed if conversion therapy is necessary to be eligible for CRS+/-HIPEC • RAS mutations and wild-type cancers can both be included. • No previous treatment for peritoneal metastatic disease
Who cannot take part
- Previous severe toxicity/allergic reactions to the systemic chemotherapy agents included in this study • Unable to tolerate full dose systemic chemotherapy treatment due to comorbidity or previous remaining toxicity (e.g. neurotoxicity) or DPYD deficiency • Deficient mismatch repair cancers are excluded • Previous CRS or HIPEC or other large open abdominal surgery leading to significant intraperitoneal adhesions. (laparoscopic procedures are ok) • Previous severe abdominal septicemia or other causes that may significantly increase the risk of intraperitoneal adhesions (a staging laparoscopy may be allowed to determine this) • Pregnant or lactating (nursing) women • Active infections requiring antibiotics • Active liver disease with positive serology for active hepatitis B, C, or known HIV • Concurrent administration of any cancer therapy other than planned study treatment within 4 weeks prior to and up to 4 weeks after study treatment • Lower and intermediate rectal cancers are excluded (above >10cm accepted) • Indication for preoperative radiation
Where in Sweden
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGothenburg, SwedenNot yet recruiting
- Region Skane Skanes UniversitetssjukhusMalmo, SwedenNot yet recruiting
- Karolinska University HospitalSolna, SwedenNot yet recruiting
- Uppsala University HospitalUppsala, SwedenNot yet recruiting
About the trial
What the trial wants to find out
To compare the difference in objective response rates (ORR) between two experimental repeat intraperitoneal chemotherapy regimens.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial
- Plain-language title
- Comparing two abdominal chemotherapy treatments for bowel cancer spread to the abdominal liningGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 15 July 2026